A couple of news stories caught my attention this week:
First, Hill-Rom Holdings and Hillenbrand began trading as separate companies this week. Hill-Rom deals in medical technology and equipment. Hillenbrand is the parent company of Batesville Casket, which positions itself as “a leader in the North American deathcare industry.”
Second, Barron's April 7th issue discusses how Wyeth's Alzheimer's Vaccine Could Become World's #1 Drug, and possibly propel the stock up over 50% over next year if the drug continues to show promise (results of the Phase II trial of 240 patients are due in June). Currently, all Alzheimer's treatments only ease symptoms whereas Wyeth's drug "could be the breakthrough the world needs for Alzheimer's. It's not going to be an incremental symptomatic improvement. If it works, it's going to be a huge leap," VP Joe Camardo says.
Comments